Please wait...


Generic Name: Scopolamine Transdermal Patch (skoe POL a meen)
Brand Name: Transderm Scop
Easy-to-read patient leaflet for Transderm Scop. Includes indications, proper use, special instructions, precautions, and possible side effects.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Transderm-scop Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
This is not a list of all drugs or health problems that interact with Transderm Scop (scopolamine transdermal patch). Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Transderm Scop (scopolamine transdermal patch) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Use Transderm Scop (scopolamine transdermal patch) as ordered by your doctor. Read all information given to you. Follow all instructions closely. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Transderm-scop Side Effects

Note: This document contains side effect information about scopolamine. Some of the dosage forms listed on this page may not apply to the brand name Transderm-Scop.

For the Consumer

Applies to scopolamine: transdermal patch extended release

Along with its needed effects, scopolamine (the active ingredient contained in Transderm-Scop) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking scopolamine:

Incidence not known

  • Blurred vision
  • chest pain or discomfort
  • difficulty with urinating
  • dilation of the pupils
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
  • eye pain
  • flushing or redness of the skin
  • mood or mental changes
  • muscle weakness
  • nausea or vomiting
  • rash
  • redness of the white part of the eyes
  • restlessness
  • seeing, hearing, or feeling things that are not there
  • shortness of breath
  • slow or irregular heartbeat
  • sweating
  • unusual tiredness
  • unusually warm skin

Get emergency help immediately if any of the following symptoms of overdose occur while taking scopolamine:

Symptoms of overdose

  • Anxiety
  • blurred or loss of vision
  • change in consciousness
  • decrease in frequency of urination
  • decrease in urine volume
  • difficulty in passing urine (dribbling)
  • disturbed color perception
  • double vision
  • dry mouth
  • dry, flushed skin
  • fast, pounding, or irregular heartbeat or pulse
  • halos around lights
  • headache
  • hyperventilation
  • irritability
  • loss of consciousness
  • nervousness
  • night blindness
  • overbright appearance of lights
  • painful urination
  • pounding in the ears
  • seizures
  • shaking
  • sleepiness
  • trouble with sleeping
  • tunnel vision
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness

For Healthcare Professionals

Applies to scopolamine: compounding powder, injectable solution, oral tablet, transdermal film extended release


Common (1% to 10%): Tachycardia

Frequency not reported: Blood pressure decreased, flushing, bradycardia, palpitations, arrhythmias, fatal acute myocardial infarction, fatal cardiac arrest


Very common (10% or more): Dry mouth (29%)

Frequency not reported: Vomiting

Nervous system

Recurrent classic migraine attacks developed in a 20-year-old naval crew member who had been treated continuously with transdermal scopolamine (the active ingredient contained in Transderm-Scop) for 5 months. The initial attack occurred within 24 hours of diagnosis of scopolamine intoxication. The patient had no self or family history of migraines. The attacks, presenting with prodrome and aura, followed by severe throbbing left headache, nausea, photophobia and sonophobia lasting 6 to 8 hours, recurred every 10 to 14 days for more than a year. Common triggers of migraines and other precipitating factors could not be identified in this case.

Very common (10% or more): Dizziness (12.4%), somnolence

Rare (less than 0.1%): Memory impairment, disturbance in attention

Postmarketing reports: Headache, amnesia, coordination abnormalities, speech disorder, vertigo


Very common (10% or more): Disturbances of visual accommodation (cycloplegia, including blurred vision, myopia, and mydriasis)

Common (1% to 10%): Visual impairment, eyelid irritation

Very rare (less than 0.01%): Pupillary dilatation which may precipitate acute glaucoma (particularly narrow angle glaucoma)

Frequency not reported: Photophobia, increased ocular pressure

Postmarketing reports: Dry eyes, eye pruritic, angle closure glaucoma, amblyopia, eyelid irritation


Common (1% to 10%): Urinary retention

Postmarketing reports: Dysuria


Common (1% to 10%): Agitation, confusion, hallucinations

Rare (less than 0.1%): Disorientation, restlessness, visual hallucinations

Postmarketing reports: Acute psychosis


Frequency not reported: Allergic reaction, anaphylactic reaction, hypersensitivity reactions, fatal anaphylactic shock


Common (1% to 10%): Skin irritation

Very rare (less than 0.01%): Generalized rash

Frequency not reported: Dyshidrosis, skin dryness, rash

Postmarketing reports: Erythema


Frequency not reported: Injection site pain

Postmarketing reports: Application site burning (patch)


Common (1% to 10%): Pharyngitis


Frequency not reported: Hyperthermia at high temperatures due to decreased sweating


Frequency not reported: Thirst

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Transderm-scop (www.drugs.com/transderm-scop.html).